Haematology and Acute Myeloid Leukaemia
Clinical research at Centre Hospitalier Universitaire Vaudois includes care for patients with acute myeloid leukaemia and related myelodysplastic syndromes, with attention to infection prevention during intensive treatment.
- Acute myeloid leukaemia
- Myelodysplastic syndromes
- High-risk haematological malignancy
The sponsor’s trial activity is centred on infectious complications that arise in the setting of haematologic cancer therapy.
Invasive Fungal Infection Prevention
Research interest extends to antifungal prophylaxis aimed at reducing invasive mold infections during the treatment period in vulnerable patients.
- Antifungal prophylaxis
- Invasive mold infections
- Proven and probable fungal infection
The clinical focus is on preventing serious fungal disease in patients exposed to prolonged immunosuppression.
Infectious Diseases in Immunocompromised Patients
The sponsor’s funded research addresses infection risk in immunocompromised patients, particularly those receiving treatment for blood cancers.
- Immunocompromised host
- Opportunistic fungal infection
- Infection risk reduction
This area reflects concern for clinical outcomes linked to severe infectious complications during oncology care.
Translational Biomarker and Risk Stratification
Research activity also includes genetic stratification and biomarker-informed approaches that may help define infection risk in patients with acute myeloid leukaemia.
- Genetic stratification
- Biomarker-guided risk assessment
- PTX3
These interests connect laboratory-based risk markers with clinical decision-making in antifungal prevention.
